European regulators recommended a subcutaneous formulation for a key anti-CD38 therapy, offering clinicians and patients more flexible administration options for multiple myeloma.

Last month, C4 Therapeutics dosed the first patient in its Phase II MOMENTUM trial of cemsidomide, combined with ...

Io Therapeutics, Inc., a privately held pharmaceutical company headquartered in Spring, Texas; announced today publication online in Scientific Reports -- Nature, of collaborative studies with Duke ...

Sanofi’s Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP to treat multiple ...

Multiple myeloma is a type of blood cancer that starts in your bone marrow. This is the soft, spongy tissue inside your bones that makes most of your blood cells. It includes plasma cells, which help ...

One year ago, Joan, my wife of 58 years, died of complications related to multiple myeloma, a blood cancer that can often go undiagnosed until it begins to seriously damage one’s health, as it ...

While it’s not as well-known as, say, leukemia or melanoma, multiple myeloma is the second most common blood cancer in adults, according to the Cancer Research Institute. “Multiple myeloma is a cancer ...

Shares of C4 Therapeutics rose after the company dosed its first patient in a Phase 1b trial for a multiple myeloma treatment. Shares were up 6.6% to $2.67 in Wednesday afternoon trading. The stock is ...

The FDA approved a steroid-sparing Tecvayli and Darzalex Faspro combo for relapsed myeloma, offering an 83% reduction in ...

Survival in myeloma is clearly being prolonged,” says Mikhael. “Whereas historically, we saw a greater impact in younger ...

Multiple myeloma care shifts to four-drug frontline regimens and MRD testing, boosting deep responses and guiding relapse ...

Your doctor tells you your multiple myeloma is in remission. But what exactly does that mean? The first thing to understand is that being in remission is not the same thing as being cured. The ...